Kietzmann Manfred, Niedorf Frank, Kramer Sabine, Hoffmann Marina, Schneider Marc, Vallé Marc, Pankow Rüdiger
Institute for Pharmacology, Toxicology and Pharmacy, University of Veterinary Medicine, Foundation, Hannover, Germany.
Berl Munch Tierarztl Wochenschr. 2011 Jan-Feb;124(1-2):83-8.
The pharmacokinetic properties of marbofoxacin, a third generation fluoroquinolone, were investigated in 12 healthy adult cats after single subcutaneous (SC) administration of 2 mg/kg BW (Part I, n=8 cats) and 4 mg/kg BW (Part II, n=4 cats). In each part of the study blood and urine samples were collected before treatment and thereafter for 5 days. The plasma and urine concentrations of marbofloxacin were determined by HPLC with UV detection. Pharmacokinetic calculations were performed for each treated animal using an open one-compartment-model with first-order elimination after SC dosing. Marbofloxacin in plasma (means): Maximum concentrations (Cmax) of about 1.2 and 3.0 microg/ml were measured 2.3 and 4 hours (tmax) after dosing of 2 and 4 mg/kg BW, respectively. Elimination from the body was low with a total clearance (Cl/F) of approximately 0.1 l/h/kg for both dosages. The half-life (t 1/2) for this process was calculated with 8-10 hours. AUC increased almost proportional when doubling the dose, i.e., 19.77 +/- 6.25 microg * h/ml (2 mg/kg BW) and 51.26 +/- 11.83 microg * h/ml (4 mg/kg BW). Plasma kinetics measured were in accordance with data from literature. Marbofloxacin in urine (means): Maximum drug concentrations were detected 4 and 8 hours after dosing with 70 microg/ml (2 mg/kg BW) and 160 microg/ml (4 mg/kg BW), respectively. Inhibitory effects of the urinary matrix on the antimicrobial activity of the drug were taken into account when performing PK/PD calculations. However, a concentration-dependent bactericidal activity (Cmax/MIC > 8-10) which is claimed for fluoroquinolones was sufficiently met with focus on Escherichia (E.) coli (MIC90 0.5 microg/ml). In the same matrix a threshold value of 1.0 microg/ml was undercut 82 and 116 hours after SC dosing, respectively. Hence, a time-dependent bacteria killing kinetic (T > MIC) which may be of relevance for some Gram-positive germs like Staphylococcus spp. (MIC90 1.0 microg/ml) should be covered, too.
在12只健康成年猫单次皮下注射2mg/kg体重(第一部分,n = 8只猫)和4mg/kg体重(第二部分,n = 4只猫)后,研究了第三代氟喹诺酮类药物马波沙星的药代动力学特性。在研究的每个部分,治疗前及之后5天采集血液和尿液样本。采用带紫外检测的高效液相色谱法测定马波沙星的血浆和尿液浓度。对每只接受治疗的动物进行药代动力学计算,采用开放的一室模型,皮下给药后按一级消除。血浆中的马波沙星(均值):分别在2mg/kg体重和4mg/kg体重给药后2.3小时和4小时(达峰时间)测得最大浓度(Cmax)约为1.2μg/ml和3.0μg/ml。两种剂量的总体清除率(Cl/F)约为0.1l/h/kg,从体内消除缓慢。该过程的半衰期(t1/2)计算为8 - 10小时。剂量加倍时,药时曲线下面积(AUC)几乎成比例增加,即19.77±6.25μg·h/ml(2mg/kg体重)和51.26±11.83μg·h/ml(4mg/kg体重)。测得的血浆动力学与文献数据一致。尿液中的马波沙星(均值):分别在给药后4小时和8小时检测到最大药物浓度,2mg/kg体重组为70μg/ml,4mg/kg体重组为160μg/ml。进行药代动力学/药效学计算时考虑了尿液基质对药物抗菌活性的抑制作用。然而,对于氟喹诺酮类药物所宣称的浓度依赖性杀菌活性(Cmax/MIC > 8 - 10),在针对大肠杆菌(MIC90 0.5μg/ml)时得到了充分满足。在相同基质中,皮下给药后82小时和116小时分别低于1.0μg/ml的阈值。因此,对于某些革兰氏阳性菌如葡萄球菌属(MIC90 1.0μg/ml)可能相关的时间依赖性细菌杀灭动力学(T > MIC)也应涵盖。